Explore the benefits of the Precision GLP-1 agonist, a new therapy that improves glycaemic control and reduces side effects.

Semaglutide is helping patients achieve weight loss previously achievable only with bariatric surgery. But at what cost?

Psoriasis and psoriatic arthritis (PsA) are chronic, immune-mediated inflammatory diseases associated with several shared common comorbidities, of which obesity is one of the most prevalent. A complex ...

Wegovy, a GLP-1 agonist for weight loss, may carry the highest risk of "eye stroke" (ischemic optic neuropathy) and sudden sight loss of the semaglutide drugs, finds an analysis of unintended side ...

A biased GLP-1 receptor agonist maintained glycemic control while reducing side effects in preclinical models. By selectively activating cAMP, this biased agonist approach may support safer diabetes ...

Treatment with GLP-1 RAs for T2D and obesity is associated with increased risk for osteoporosis, gout, and osteomalacia compared with nonuse.

If you’re looking for ways to mitigate your risk of developing cardiovascular disease or experiencing a cardiac event, such as a heart attack or stroke, glucagon-like peptide-1 (GLP-1) receptor ...

It’s no secret that starting a GLP-1 weight-loss medication is as much an emotional journey as it is a physical one. From navigating inevitable ups and downs to quashing cravings and finding the ...

Research has suggested that GLP-1 receptor agonists may have protective effects against certain eye conditions, but they have also been linked to rare ophthalmic complications. In this retrospective ...

Results show increased long-term risk for osteoporosis, gout and osteomalacia in one study; improved postoperative outcomes for common orthopaedic procedures in another NEW ORLEANS, March 2, 2026 ...